Blood test may spare lung cancer patients from chemo
NCT ID NCT07360743
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This study tests whether a blood test can identify people with advanced lung cancer who can be treated with immunotherapy alone instead of chemotherapy plus immunotherapy. The trial enrolls 275 adults with high PD-L1 levels and a low inflammation blood score. The goal is to see if these patients can avoid early tumor growth and enjoy longer-lasting benefits from treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER (SQUAMOUS OR NON SQUAMOUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHP-Hôpital Ambroise Paré
Boulogne-Billancourt, 92100, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Institut Bergonie Bordeaux
Bordeaux, 33076, France
-
Institut Gustave Roussy
Villejuif, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.